Food and Drug Administration, HHS.
The Food and Drug Administration (FDA) is withdrawing approval of four new drug applications (NDAs) and two abbreviated new drug applications (ANDAs) from multiple applicants. The holders of the applications notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.
Effective Date: January 30, 2017.
Start Further Info
FOR FURTHER INFORMATION CONTACT:
Florine P. Purdie, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, Rm. 6248, Silver Spring, MD 20993-0002, 301-796-3601.
End Further Info
Start Supplemental Information
The holders of the applications listed in the table have informed FDA that these drug products are no longer marketed and have requested that FDA withdraw approval of the applications pursuant to the process in § 314.150(c) (21 CFR 314.150(c)). The applicants have also, by their requests, waived their opportunity for a hearing. Withdrawal of approval of an application or abbreviated application under § 314.150(c) is without prejudice to refiling.Start Printed Page 96005
|NDA 019080||ProSom (estazolam) Tablets, 1 milligram (mg) and 2 mg||Abbott Laboratories, 200 Abbott Park Rd., Abbott Park, IL 60064.|
|NDA 020195||Fentanyl Oralet (fentanyl citrate) Troche/Lozenge, Equivalent to (EQ) 0.1 mg base, EQ 0.2 mg base, EQ 0.3 mg base, and EQ 0.4 mg base||Cephalon, Inc., 41 Moores Rd., Frazer, PA 19355.|
|NDA 021726||Niravam (alprazolam) Orally Disintegrating Tablets, 0.25 mg, 0.5 mg, 1 mg, and 2 mg||UCB, Inc., 1950 Lake Park Dr., Building 2100, Smyrna, GA 30080.|
|ANDA 084287||Methyltestosterone Tablets USP, 10 mg||Impax Laboratories, Inc., 31047 Genstar Rd., Hayward, CA 94544.|
|ANDA 084310||Methyltestosterone Tablets USP, 25 mg|| Do.|
|NDA 205208||Desvenlafaxine Fumarate Extended-Release Tablets, EQ 50 mg base and EQ 100 mg base||Teva Pharmaceuticals USA, Inc., 425 Privet Rd., Horsham, PA 19044.|
Therefore, under section 505(e) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 355(e)) and under authority delegated to the Director, Center for Drug Evaluation and Research, by the Commissioner, approval of the applications listed in the table, and all amendments and supplements thereto, is hereby withdrawn, effective January 30, 2017. Introduction or delivery for introduction into interstate commerce of products without approved new drug applications violates section 301(a) and (d) of the FD&C Act (21 U.S.C. 331(a) and (d)). Drug products that are listed in the table that are in inventory on the date that this notice becomes effective (see the DATES section) may continue to be dispensed until the inventories have been depleted or the drug products have reached their expiration dates or otherwise become violative, whichever occurs first.
End Supplemental Information
Dated: December 23, 2016.
Associate Commissioner for Policy.
[FR Doc. 2016-31625 Filed 12-28-16; 8:45 am]
BILLING CODE 4164-01-P